Navigation Links
Newly found sensing system enables certain bacteria to resist human immune defenses

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, have discovered a survival mechanism in a common type of bacteria that can cause illness. The mechanism lets the bacteria protect itself by warding off attacks from antimicrobial peptides (AMPs), which are defense molecules sent by the body to kill bacteria.

Bacteria are divided into two types, gram-positive and gram-negative, with the primary difference being the nature of the bacterial cell wall. Little is known about how gram-positive bacteria—such as those that can lead to food poisoning, skin disorders and toxic shock—avoid being killed by AMPs. AMPs are made by virtually all groups of organisms, including amphibians, insects, several invertebrates and mammals, including humans.

“Gram-positive bacteria are major threats to human health, especially due to increasing problems with drug resistance, and these findings may help chart a path to designing new drugs to bolster our antimicrobial treatment options,” notes NIAID Director Anthony S. Fauci, M.D.

Led by Michael Otto, Ph.D., of NIAID’s Rocky Mountain Laboratories (RML), the scientists used the gram-positive bacterium Staphylococcus epidermidis to study its response to a specific human AMP, human beta defensin 3. S. epidermidis is one of several hard-to-treat infectious agents that can be transmitted to patients in hospitals via contaminated medical implants. Findings by Dr. Otto’s research group are published in the May 29 issue of the Proceedings of the National Academy of Science. Other well-known types of gram-positive bacteria include agents that cause anthrax, strep throat, flesh-eating disease and various types of food poisoning.

In gram-negative bacteria—such as those that cause plague and salmonellosis—a sensory and gene regulation system named PhoP/PhoQ protects invading bacteria, and scientists believe if they develop a better und erstanding of this system they could develop new drugs that are more effective at protecting people from infection.

Likewise, now Dr. Otto and his research group are hoping for similar possibilities for gram-positive bacteria with their discovery of “aps,” which stands for antimicrobial peptide sensor. Aps has three parts: apsS, the sensor region; apsR, the gene regulation region; and apsX, which has an unknown function that Dr. Otto’s group is investigating. Studies show that all three components of aps must be present for the system to function and effectively protect bacteria from AMPs.

“We are aware that for gram-negative bacteria, PhoP/PhoQ has been called a premier target for antimicrobial drug discovery, but little corresponding work has been done with gram-positive bacteria,” Dr. Otto says. “Our group is excited by what we have demonstrated—an efficient and unique way that gram-positive bacteria control resistance—and we are continuing our investigation of the aps sensing system being used for drug development.”


'"/>

Source:NIH/National Institute of Allergy and Infectious Diseases


Related biology news :

1. Newly-discovered class of genes determines ?and restricts ?stem cell fate
2. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
3. Newly Discovered Compound Blocks Known Cancer-Causing Protein
4. Newly discovered pathway might help in design of cancer drugs
5. Newly Discovered Branding Process Helps Immune System Cells Pick Their Fights
6. Newly discovered protein an important tool for sleeping sickness research
7. Newly discovered genetic disease sheds light on bodys water balance
8. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
9. Newly recognized gene mutation may reduce seeds, resurrect plants
10. Newly discovered birdlike dinosaur is oldest raptor ever found in South America
11. Fitting in: Newly evolved genes adopt a variety of strategies to remain in the gene pool

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/11/2017)... Iowa , Jan. 11, 2017 Intoxalock, ... first with the release of its patent-pending calibration device. ... and reliably perform calibrations, securely upload data logs and ... for the customer. "Fighting drunk driving through ... for the public at large, but also for the ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... , January 20, 2017 ... cancer is one of leading causes of death worldwide. ... Although the number of cancer related deaths increased gradually ... Rising in incidence rate of various cancers continues to ... a research report by Global Market Insights, Inc. cancer ...
(Date:1/19/2017)... Future has a half cooked research report on Global Liquid Biopsy ... expected to reach USD 450 Million by the end of the ... ... as a swiftly growing market and expected that the market will ... has been a tremendous growth in the prevalence of cancer disease ...
(Date:1/19/2017)... 19, 2017 Research and Markets ... has announced the addition of the ... Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market trends ... using estimated market values as the base numbers Key ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
Breaking Biology Technology: